Longeveron Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Longeveron Inc Company

Longeveron Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The Company is primarily focused on three pipeline indications, which include Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty. Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The Company has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.

Longeveron Inc Info



Ticker SymbolLGVN

Company nameLongeveron Inc

IPO dateFeb 12, 2021

CEOMr. Wa'el Hashad

Number of employees25

Security typeOrdinary Share

Fiscal year-endFeb 12

Address1951 NW 7th Ave

CityMIAMI

Stock exchangeNASDAQ Capital Market Consolidated

CountryUnited States of America

Postal code33136

Phone13053027158

Websitehttps://www.longeveron.com/

Ticker SymbolLGVN

IPO dateFeb 12, 2021

CEOMr. Wa'el Hashad

Company Executives of Longeveron Inc



Name

Name/Position

Position

Shareholding

Change

Dr. Joshua M. Hare, M.D.

Executive Chairman of the Board, Co-Founder, Chief Science Officer

253.07K

-2.03%

Ms. Lisa Locklear

Chief Financial Officer, Treasurer

152.42K

-7.23%

Dr. Nataliya Agafonova, M.D.

Chief Medical Officer

140.15K

-7.82%

Mr. Devin Blass

Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls

102.54K

-6.91%

Mr. Khoso Baluch

Independent Director

41.36K

+39.76%

Ms. Ursula Ungaro, J.D.

Independent Director

35.55K

+91.64%

Mr. Richard N. Kender

Independent Director

22.33K

+318.71%

Mr. Roger Joseph Hajjar

Independent Director

21.00K

+425.00%

Ms. Neha Motwani

Independent Director

21.00K

+425.00%

Dr. George Paletta

Director

--

Name

Name/Position

Position

Shareholding

Change

Dr. Joshua M. Hare, M.D.

Executive Chairman of the Board, Co-Founder, Chief Science Officer

253.07K

-2.03%

Ms. Lisa Locklear

Chief Financial Officer, Treasurer

152.42K

-7.23%

Dr. Nataliya Agafonova, M.D.

Chief Medical Officer

140.15K

-7.82%

Mr. Devin Blass

Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls

102.54K

-6.91%

Mr. Khoso Baluch

Independent Director

41.36K

+39.76%

Ms. Ursula Ungaro, J.D.

Independent Director

35.55K

+91.64%

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

By BusinessUSD

Name

Revenue

Proportion

Clinical trial revenue

298.00K

94.30%

Contract manufacturing

12.00K

3.80%

Contract manufacturing lease revenue

6.00K

1.90%

No Data

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Clinical trial revenue

298.00K

94.30%

Contract manufacturing

12.00K

3.80%

Contract manufacturing lease revenue

6.00K

1.90%

Shareholding Stats

Updated: Wed, Oct 29

Shareholders

Shareholder Types

Shareholders

Proportion

Lincoln Alternative Strategies LLC

6.01%

Armistice Capital LLC

3.45%

Lehr (Paul T)

1.66%

Hashad (Mohamed Wa'el Ahmed)

1.59%

Hare (Joshua M)

1.29%

Other

85.99%

Shareholders

Proportion

Lincoln Alternative Strategies LLC

6.01%

Armistice Capital LLC

3.45%

Lehr (Paul T)

1.66%

Hashad (Mohamed Wa'el Ahmed)

1.59%

Hare (Joshua M)

1.29%

Other

85.99%

Shareholder Types

Shareholders

Proportion

Individual Investor

9.26%

Corporation

6.01%

Hedge Fund

3.96%

Investment Advisor

1.66%

Investment Advisor/Hedge Fund

1.09%

Venture Capital

0.25%

Bank and Trust

0.02%

Other

77.75%

Institutional Shareholding



Updated: Sun, Oct 5

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

58

1.37M

6.98%

+569.67K

2025Q2

73

2.18M

16.11%

+296.38K

2025Q1

73

2.14M

15.82%

-119.71K

2024Q4

73

2.53M

18.80%

+652.31K

2024Q3

67

2.33M

17.58%

+1.38M

2024Q2

67

924.88K

16.16%

+194.99K

2024Q1

64

168.05K

15.95%

-258.83K

2023Q4

68

363.47K

37.19%

+110.22K

2023Q3

73

198.13K

31.46%

-72.89K

2023Q2

70

193.49K

31.19%

-39.22K

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Lincoln Alternative Strategies LLC

1.18M

6.01%

+1.18M

--

Aug 08, 2025

Armistice Capital LLC

676.23K

3.45%

+676.23K

--

Sep 30, 2024

Lehr (Paul T)

330.30K

2.42%

+100.44K

+43.69%

Jul 15, 2025

Hashad (Mohamed Wa'el Ahmed)

310.90K

1.59%

+166.85K

+115.83%

Jul 15, 2025

Hare (Joshua M)

253.07K

1.29%

-5.25K

-2.03%

May 16, 2025

Soffer (Rock J)

179.52K

0.92%

+17.00K

+10.46%

Jul 15, 2025

Locklear (Lisa)

164.30K

0.85%

+11.77K

+7.71%

Aug 11, 2025

The Vanguard Group, Inc.

144.27K

0.74%

--

Jun 30, 2025

Geode Capital Management, L.L.C.

141.50K

0.72%

+770.00

+0.55%

Jun 30, 2025

Agafonova (Nataliya)

152.03K

1.12%

+94.57K

+164.57%

Jul 15, 2025

Related ETFs



Updated: Sun, Nov 2

Name

Proportion

iShares Micro-Cap ETF

0%

iShares Micro-Cap ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

Mar 19, 2024

Merger

10→1

Mar 19, 2024

Merger

10→1

Mar 19, 2024

Merger

10→1

Mar 19, 2024

Merger

10→1

Date

Type

Ratio

Mar 19, 2024

Merger

10→1

Mar 19, 2024

Merger

10→1

Mar 19, 2024

Merger

10→1

Mar 19, 2024

Merger

10→1